TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30036194

Group type: EXPERIMENTAL
Intervention: Regular exercise as an adjuvant treatment in myopathies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High intensity exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise (specific modes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise (in dysferlinopathy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exoskeletons and antigravity trainers
Number of subjects: 0
Study: 26756107

Group type: EXPERIMENTAL
Intervention: Prophylactic ampicillin
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 25514273

Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 35

Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 35

Group type: COMPARATOR
Intervention: Shoes
Number of subjects: 35
Study: 22248605

Group type: EXPERIMENTAL
Intervention: Wire-guided cannulation (WGC) with sphincterotome (S)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional methods (C)
Number of subjects: 400
Study: 19464824

Group type: EXPERIMENTAL
Intervention: Pretreatment FDG-PET
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no FDG-PET)
Number of subjects: 129
Study: 17148938

Group type: EXPERIMENTAL
Intervention: Valproate treatment for 6 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 14
Study: 15886473

Group type: EXPERIMENTAL
Intervention: HA in combination with DOX (30-60 mg/m2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HA in combination with 5-FU (cumulative dose of 1,350-2,250 mg/m2 per cycle)
Number of subjects: 30

Group type: COMPARATOR
Intervention: HA/chemotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 30
Study: 12070557

Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg/day orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (30 mg/day orally)
Number of subjects: 0
Study: 10049988

Group type: EXPERIMENTAL
Intervention: PSV (pressure support ventilation) during CPT
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control session (no PSV)
Number of subjects: 16
Study: 7596622

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine (titrated from 0.1 to 0.3 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 41
Study: 2193993

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.25% eyedrops
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 16
Study: 369298

Group type: EXPERIMENTAL
Intervention: Flupenthixol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study: 30954691

Group type: EXPERIMENTAL
Intervention: 5 mL/kg of 3% saline (hypertonic group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: 10 mL/kg of 0.9% saline (isotonic group)
Number of subjects: 65
Study: 27737489

Group type: EXPERIMENTAL
Intervention: Serial Combined Training Group (SCG)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Integrated Combined Training Group (ICG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 54
Study: 26141464

Group type: EXPERIMENTAL
Intervention: Preoperative eradication regimen: rabeprazole, amoxicillin, and clarithromycin before surgery
Number of subjects: 142

Group type: COMPARATOR
Intervention: Postoperative eradication regimen: rabeprazole, amoxicillin, and clarithromycin after postoperative day 8
Number of subjects: 142
Study: 23625100

Group type: EXPERIMENTAL
Intervention: Kangaroo holding (skin-to-skin between mother's breasts)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Blanket holding (held in mother's arms)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (no holding restrictions)
Number of subjects: 87
Study: 21276583

Group type: EXPERIMENTAL
Intervention: Angry faces in temporal bisection task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angry faces in verbal estimation task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angry faces in production task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral faces in temporal bisection task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral faces in verbal estimation task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral faces in production task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angry faces in temporal generalization task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angry faces in reproduction task
Number of subjects: 0
Study: 18704672

Group type: EXPERIMENTAL
Intervention: Standard story format
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Directive story format
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control story condition
Number of subjects: 45
Study: 16399189

Group type: EXPERIMENTAL
Intervention: Coblator
Number of subjects: 134

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 134

Group type: COMPARATOR
Intervention: Ultrasonic Scalpel
Number of subjects: 134
Study: 15230027

Group type: EXPERIMENTAL
Intervention: Mailed information pamphlet
Number of subjects: 0

Group type: COMPARATOR
Intervention: No mailed pamphlet (usual care)
Number of subjects: 0
Study: 11724129

Group type: EXPERIMENTAL
Intervention: 20 mL of gel containing 2% lidocaine
Number of subjects: 147

Group type: COMPARATOR
Intervention: 20 mL of gel without lidocaine
Number of subjects: 147

Group type: COMPARATOR
Intervention: 10 mL of gel containing 2% lidocaine
Number of subjects: 147

Group type: COMPARATOR
Intervention: 10 mL of gel without lidocaine
Number of subjects: 147
Study: 9446253

Group type: EXPERIMENTAL
Intervention: G-CSF, 2.5 micrograms/kg/day s.c. for the first 3 days followed by GM-CSF, 2.5 micrograms/kg/day s.c. for the last 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: G-CSF, 2.5 micrograms/kg/day s.c. from the 8th day to the 13th day of cycle
Number of subjects: 0
Study: 8323356

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment for one week
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 41
Study: 2877043

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 30110706

Group type: EXPERIMENTAL
Intervention: 0.067 mg/kg/day r‐hGH for 12 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: 6 months of no treatment followed by 0.067 mg/kg/day r‐hGH for 6 months
Number of subjects: 90
Study: 27997608

Group type: EXPERIMENTAL
Intervention: Peripheral Electrical Stimulation (PES) treatment (1.33Hz/16Hz burst mode), for 14 days
Number of subjects: 12
Study: 26098483

Group type: EXPERIMENTAL
Intervention: Fenugreek seeds (10 g/d)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (5 g/d of wheat starch)
Number of subjects: 88
Study: 22960615

Group type: EXPERIMENTAL
Intervention: New silicone hydrogel SCLs
Number of subjects: 417
Study: 20182424

Group type: EXPERIMENTAL
Intervention: AM103 (50-1000 mg single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AM103 (50-1000 mg once daily for 11 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AM103 (all doses)
Number of subjects: 0
Study: 18442848

Group type: EXPERIMENTAL
Intervention: Natural categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artifactual categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulation of perceptual vs. functional features
Number of subjects: 0
Study: 15721724

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 70
Study: 14682086

Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 11018854

Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/day (T100)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg/day (T200)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 9277651

Group type: EXPERIMENTAL
Intervention: Progesterone 45 mg vaginal gel (group A, n = 14)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Progesterone 90 mg vaginal gel (group B, n = 13)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Progesterone 180 mg vaginal gel (group C, n = 13)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Estradiol (E2) administered for 28 days prior to progesterone treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Endometrial biopsy performed on day 20 or 24
Number of subjects: 40
Study: 8510910

Group type: EXPERIMENTAL
Intervention: Augmented group (severing the medial check ligaments and intermuscular membranes)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Nonaugmented group (no surgery on medial check ligaments or intermuscular membranes)
Number of subjects: 101
Study: 3016439

Group type: EXPERIMENTAL
Intervention: Yohimbine (125 micrograms/kg, then 1 microgram/kg/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study: 29235664

Group type: EXPERIMENTAL
Intervention: Immersion PUVA
Number of subjects: 60

Group type: COMPARATOR
Intervention: NB-UVB
Number of subjects: 60
Study: 27506771

Group type: EXPERIMENTAL
Intervention: Oral 35,000 IU/week vitamin D3
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 24773191

Group type: EXPERIMENTAL
Intervention: RTR+ (a modified version of Reducing the Risk curriculum)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: RTR (Reducing the Risk curriculum)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: RTR+
Number of subjects: 734
Study: 23813984

Group type: EXPERIMENTAL
Intervention: Inhibitory 1 Hz rTMS over the right triangular part of the posterior inferior frontal gyrus
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study: 20606518

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3 months of vigorous aerobic exercise at 80% to 85% of maximal heart rate, supervised 3 times per week)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nonaerobic (no aerobic exercise)
Number of subjects: 39
Study: 18307608

Group type: EXPERIMENTAL
Intervention: Recruit and match/randomize procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Match/randomize and recruitment procedure
Number of subjects: 0
Study: 15926164

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 45
Study: 12674587

Group type: EXPERIMENTAL
Intervention: Antihypertensive and hypolipidemic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lowering blood pressure below 140/90 mm Hg and LDL‐cholesterol below 3 mmol/l (or even < 2.6 mmol/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk factor assessment including gender, age, family history, smoking, diabetes, blood pressure, total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride
Number of subjects: 0
Study: 10955849

Group type: EXPERIMENTAL
Intervention: Most patent nasal cavity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Least patent nasal cavity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total clearance of radiolabeled saline
Number of subjects: 0
Study: 8826868

Group type: COMPARATOR
Intervention: 5-FU alone (arm A)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 5-FU + IFN (arm B)
Number of subjects: 141
Study: 29332235

Group type: EXPERIMENTAL
Intervention: Daily diaries
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Weekly diaries
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control (no diaries)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Diary participants (combined)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Weekly automated feedback
Number of subjects: 324
Study: 27493132

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 835

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 835
Study: 25515244

Group type: EXPERIMENTAL
Intervention: 1% squalamine ointment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23761652

Group type: EXPERIMENTAL
Intervention: FeSO4-fortified meals
Number of subjects: 52

Group type: COMPARATOR
Intervention: Mixture of NaFeEDTA and FeSO4
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: FeSO4-fortified meals with extra ascorbic acid (AA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: FeSO4-fortified meals with standard AA concentration
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: FeSO4-fortified meals with phytase without extra AA
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: FeSO4-fortified meals with phytase with extra AA
Number of subjects: 52

Group type: COMPARATOR
Intervention: FeSO4-fortified meals without phytase
Number of subjects: 52
Study: 21416311

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine IV (0.5 μg/kg bolus over 10 min and 0.5 μg/kg/h infusion) with local anesthesia (lidocaine 2% with epinephrine)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Epidural anesthesia (15 ml of 0.25% bupivacaine + 100 μg fentanyl)
Number of subjects: 49
Study: 18575012

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS) in group B (2004)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Non-computer-assisted surgery in group A (2003)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 123
Study: 16012523

Group type: EXPERIMENTAL
Intervention: Surgery followed by adjuvant radiotherapy (60 Gy over 30 fractions)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Concurrent combination chemotherapy and radiotherapy (66 Gy in 33 fractions)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Surgery followed by adjuvant radiotherapy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Concurrent combination chemotherapy and radiotherapy
Number of subjects: 119
Study: 11810100

Group type: EXPERIMENTAL
Intervention: High volume of exercise in mid and late pregnancy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Reduced exercise volume after the 20th week
Number of subjects: 75
Study: 10365740

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Dalteparin)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Both groups (Dalteparin and Placebo)
Number of subjects: 314
Study: 7486898

Group type: EXPERIMENTAL
Intervention: Coca-Cola Classic (240 ml) with ketoconazole (200 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water with ketoconazole (200 mg) (control)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Water with ketoconazole (200 mg) after omeprazole (60 mg)
Number of subjects: 9
Study: 2044949

Group type: EXPERIMENTAL
Intervention: Semantic elaboration
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Interactive imagery
Number of subjects: 714

Group type: COMPARATOR
Intervention: Control
Number of subjects: 714
Study: 6262930

Group type: EXPERIMENTAL
Intervention: Cefazoline (1 gram) administered 30 minutes before operation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Untreated cases (control group)
Number of subjects: 59
Study: 30976797

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 28891900

Group type: COMPARATOR
Intervention: Closed reduction of zygomatic arch fractures (Group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Closed reduction with C‐arm fluoroscan and balloon support (Group B)
Number of subjects: 32
Study: 25432641

Group type: EXPERIMENTAL
Intervention: Temperature-controlled radiofrequency (TCRF)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Bipolar radiofrequency (BRF)
Number of subjects: 84
Study: 25077100

Group type: EXPERIMENTAL
Intervention: Automated blood pressure measurement in physician's office (Group A)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Automated blood pressure measurement in pharmacy (Group B)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Automated blood pressure measurement in both settings
Number of subjects: 275
Study: 21509053

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerine (NEDV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flow-mediated vasodilation (EDV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NEDV and EDV in hypertensive patients
Number of subjects: 0
Study: 19644897

Group type: EXPERIMENTAL
Intervention: Silver ring splints (SRS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Commercial prefabricated thermoplastic splints (PTS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SRS
Number of subjects: 50

Group type: COMPARATOR
Intervention: PTS
Number of subjects: 50
Study: 17103167

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radio-chemotherapy (NARCT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Reduction in the standardized uptake value (SUV) of more than 80%
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Progressive disease according to PET
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Complete tumour resection
Number of subjects: 70
Study: 15136318

Group type: EXPERIMENTAL
Intervention: Timolol maleate and dorzolamide hydrochloride (timolol-dorzolamide)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Timolol alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dorzolamide alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11352855

Group type: EXPERIMENTAL
Intervention: Very low activity genotype of mEH
Number of subjects: 974

Group type: EXPERIMENTAL
Intervention: mEH genotype and cumulative smoking interaction
Number of subjects: 974
Study: 9158268

Group type: EXPERIMENTAL
Intervention: Desmopressin (30 micrograms/day for three weeks)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Imipramine (0.9 mg/kg for three weeks)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Imipramine followed by Desmopressin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Desmopressin followed by Imipramine
Number of subjects: 57
Study: 7689205

Group type: EXPERIMENTAL
Intervention: Sotalol (2.0‐2.9 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Flecainide (2.5‐3.3 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Verapamil (3.3‐3.7 mg/kg)
Number of subjects: 6
Study: 3310763

Group type: EXPERIMENTAL
Intervention: Normomagnesemic group (4 out of 9)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hypermagnesemic group (8 patients)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hypomagnesemic group (5 patients)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall cardiac arrest victims (13 out of 22)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (19 matched controls)
Number of subjects: 22
Study: 29552010

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA (ω‐3) supplementation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 22
Study: 28221819

Group type: EXPERIMENTAL
Intervention: Endoscopic Injection Sclerotherapy (EIS)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Endoscopic Variceal Ligation (EVL)
Number of subjects: 124
Study: 26790797

Group type: EXPERIMENTAL
Intervention: High‐flexion posterior stabilized mobile bearing design (HF‐PS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard cruciate retaining fixed bearing design (CR)
Number of subjects: 47
Study: 23489103

Group type: EXPERIMENTAL
Intervention: Halita™ mouthrinse
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: meridol(®) mouthrinse
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Halita™ with zinc lactate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: meridol(®) with zinc lactate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 36

Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 36
Study: 21251856

Group type: EXPERIMENTAL
Intervention: Tailored web-based intervention providing individualized audit data and peer comparisons
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Tailored web-based intervention
Number of subjects: 46
Study: 18475293

Group type: EXPERIMENTAL
Intervention: Paclitaxel poliglumex (PPX) 175 mg m(‐2)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Paclitaxel poliglumex (PPX) 210 mg m(‐2)
Number of subjects: 849

Group type: COMPARATOR
Intervention: Docetaxel 75 mg m(‐2)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Paclitaxel poliglumex (PPX)
Number of subjects: 849

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 849
Study: 16606640

Group type: EXPERIMENTAL
Intervention: Central assessment by three blinded embryologists using 2D images
Number of subjects: 688

Group type: COMPARATOR
Intervention: Local assessment versus consolidated central assessment (different methods)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Consolidated central assessment by three embryologists
Number of subjects: 688
Study: 12355999

Group type: EXPERIMENTAL
Intervention: Thiazide‐like diuretic, slow‐release indapamid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Converting enzyme inhibitor, enalapril 20 mg
Number of subjects: 0
Study: 10692717

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg tablets
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study: 8941836

Group type: EXPERIMENTAL
Intervention: Home-use carbamide peroxide tooth-whitening procedure
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 52
Study: 1765336

Group type: EXPERIMENTAL
Intervention: Working sample using a method combining multiple regression analysis, morphological measurements, and logarithmic data transformation.
Number of subjects: 317

Group type: COMPARATOR
Intervention: Control sample tested with the derived formulae.
Number of subjects: 317